Knight Therapeutics Inc. Announces Triumvira Loan Repayment
MONTREAL, April 16, 2020 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX:GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, announced today that privately-held Triumvira Immunologics Inc. (“Triumvira”) has repaid the outstanding loan balance of US$5 million issued in 2019.
In addition, Knight continues to hold rights to commercialize Triumvira’s future approved products in select countries if certain conditions are met.“We are pleased to have supported Triumvira in advancing the development of a novel platform for engineering T cells to attack cancer while generating solid returns for Knight shareholders,” said Jonathan Ross Goodman, Chief Executive Officer of Knight.About Knight Therapeutics Inc. Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing innovative pharmaceutical products for Canada and Latin America. Knight owns a controlling stake in Grupo Biotoscana, a pan-Latin American specialty pharmaceutical company. Knight Therapeutics Inc.’s shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company’s web site at www.gud-knight.com or www.sedar.com.Forward Looking StatementThis document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.’s Annual Report and in Knight Therapeutics Inc.’s Annual Information Form for the year ended December 31, 2019. Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events, except as required by law.CONTACT INFORMATION:Knight Therapeutics Inc.
T: 514-678- 8930
Email: [email protected]